Patient-Derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 295
Abstract
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting-edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDX) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to preclinical drug testing and biomarker identification in a number of cancers including ovarian, pancreatic, breast and prostate cancers. These models have been shown to be biologically stable and accurately reflect the patient tumor with regards to histopathology, gene expression, genetic mutations and therapeutic response. However, pre-clinical analyses of molecularly annotated PDX models derived from high-grade serous ovarian cancer (HG-SOC) remain limited. In vivo response to conventional and/or targeted therapeutics has only been described for very small numbers of individual HG-SOC PDX in conjunction with sparse molecular annotation and patient outcome data. Recently, two consecutive panels of epithelial ovarian cancer PDX correlate in vivo platinum response with molecular aberrations and source patient clinical outcomes. These studies underpin the value of PDX models to better direct chemotherapy and predict response to targeted therapy. Tumor heterogeneity, before and following treatment, as well as the importance of multiple molecular aberrations per individual tumor underscore some of the important issues addressed in PDX models.Keywords
This publication has 52 references indexed in Scilit:
- Origin of the vasculature supporting growth of primary patient tumor xenograftsJournal of Translational Medicine, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Phenotypic heterogeneity and instability of human ovarian tumor-initiating cellsProceedings of the National Academy of Sciences, 2011
- Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutationBritish Journal of Cancer, 2010
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- Ovarian CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive BiomarkersClinical Cancer Research, 2008
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesBMC Cancer, 2008
- Models of ovarian cancer metastasis: Murine modelsDrug Discovery Today: Disease Models, 2006
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001